USANA Health Sciences
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), USANA Health Sciences beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share increased significantly.
Gross margins dropped, operating margins expanded, net margins expanded.
USANA Health Sciences tallied revenue of $165.2 million. The four analysts polled by S&P Capital IQ predicted revenue of $160.8 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $143.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.18. The five earnings estimates compiled by S&P Capital IQ predicted $1.06 per share. GAAP EPS of $1.18 for Q3 were 46% higher than the prior-year quarter's $0.81 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 81.6%, 80 basis points worse than the prior-year quarter. Operating margin was 14.6%, 150 basis points better than the prior-year quarter. Net margin was 10.6%, 200 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $161.9 million. On the bottom line, the average EPS estimate is $1.13.
Next year's average estimate for revenue is $637.7 million. The average EPS estimate is $4.20.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 212 members out of 392 rating the stock outperform, and 180 members rating it underperform. Among 123 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give USANA Health Sciences a green thumbs-up, and 75 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on USANA Health Sciences is outperform, with an average price target of $53.80.
- Add USANA Health Sciences to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Nu Skin Enterprises, USANA Health Sciences, and ReachLocal Are Today's 3 Best Stocks
The S&P 500 gets hit on weaker China growth prospects and biotech weakness while Nu Skin, USANA Health Sciences, and ReachLocal all vaulted higher.
If the FTC Slams Herbalife, These Stocks Could Get Hit Hard
A successful takedown of Herbalife could devastate the stocks of other multilevel-marketing companies, including Nu Skin, Usana, Primerica, and even Avon Products.
Why Geron, Express, and Herbalife Tumbled Today
The S&P 500 managed to end a two-day losing streak Wednesday with very modest gains, but many stocks couldn't recover from severe losses. Find out what made these three stocks drop today.